ArticleCureus2025
Evaluating the Efficacy and Safety of Anidulafungin and Caspofungin in Invasive Candida Infections in Intensive Care Units in India: A Prospective, Observational, Multicenter, Open-Label Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive Candida infections are a significant concern in ICU patients, with mortality rates ranging from 30-50%. This study aimed to assess the demographic and risk factors, as well as the safety and efficacy of anidulafungin and caspofungin in treating invasive Candida infections in ICU patients. METHODOLOGY: This prospective, observational, multicenter, open-label study was conducted across four hospitals in India to evaluate the safety and efficacy of anidulafungin and caspofungin in adult ICU patients with confirmed or suspected invasive Candida infections. Patients aged ≥18 years were treated with either anidulafungin or caspofungin. Data were collected on sociodemographic characteristics, medical history, medications, and clinical outcomes, including hospital stay, treatment duration, and clinical and microbiological responses. Efficacy assessment is based on clinical and microbiologic success. Clinical success is defined as the resolution of signs and symptoms of invasive candidiasis, and microbiologic success is defined as the eradication of Candida species present at baseline, as determined on follow-up culture. A positive global response refers to both clinical and microbiologic success.
resultsA total of 44 patients received anidulafungin and 18 received caspofungin. The mean age for anidulafungin-treated patients was 61.1±14.1 years, while for caspofungin-treated patients, it was 56.6±14.3 years. Anidulafungin achieved a clinical success rate of 34.9%, microbiological success of 34.9%, and a global response rate of 46.5%. Caspofungin showed clinical success of 50%, microbiological success of 70.7%, and a global response rate of 47.1%.
conclusionsThe study showed that anidulafungin is effective in treating invasive candida infections and could be an equivalent alternative in terms of efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.